SEC Based Method for Size Determination of Immune Complexes of Therapeutic Antibodies in Animal Matrix
Open Access
- 31 July 2016
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2016, 1-9
Abstract
Therapeutic monoclonal antibodies (mAbs) represent a milestone in pharmacological development. Their superiority is based on the combination of high specificity, low toxicity, and long half-life that characterizes biologics. If biologics have Achilles’ heel, it is their potential immunogenicity. To better understand the impact of the size of immune complexes of mAbs on anti-drug antibody (ADA) dependent adverse reactions inMacaca fascicularis, we developed an efficient high-throughput size exclusion chromatography- (SEC-) based methodology that enables analysis of the size, size distribution, and ratio of free and ADA-complexed mAb in serum allowing for assessment of formation and clearance of circulating ADA-mAb immune complexes (CIC).Keywords
This publication has 19 references indexed in Scilit:
- Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune ComplexesFrontiers in Immunology, 2016
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysisAnnals of the Rheumatic Diseases, 2013
- Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2011
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanerceptAnnals of the Rheumatic Diseases, 2011
- Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studiesRegulatory Toxicology and Pharmacology, 2009
- Immunogenicity of Anti-TNF-α Agents in Autoimmune DiseasesClinical Reviews in Allergy & Immunology, 2009
- Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulinNature Biotechnology, 2007
- Immunogenicity of infliximab: how to handle the problem?2007
- Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003